MTx is an innovator in the field of antibody discovery and immune repertoire analysis. Our antibody discovery platform DROPZYLLA® uses robust, simple, and fast microfluidic single-cell technologies to enable antibody repertoire mining and mAb discovery at unprecedented efficiency and speed.

Products, services, technology

The company’s current pipeline features programs in transplant virology and immuno-oncology. mAb “AntiBKV” is currently in clinical development for the treatment of BK polyomavirus infection in kidney transplant recipients.

Cooperation possibilities

Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery from human and animal species across all indications for proprietary and partnered projects.

 

Location
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2012
  • Number of employees in Switzerland
    1-9
Key business